Report Library
All ReportsDatamonitor Pneumococcal Vaccines KOL Interview
July 27, 2016
Datamonitor interviewed three infectious diseases specialists to determine the physicians'
views on marketed and pipeline pneumococcal vaccines. Two physicians were based in Chicago, IL and one in the UK. The three interviews were combined into a single report.
If you are a KOL Insight Subscriber, please access the first, second and third report from our KOL Insight portal (Subscribers only).
Highlights
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the first, second and third report from our KOL Insight portal (Subscribers only).
Highlights
- Likelihood of a new serotype shift in pneumococcal disease.
- Sales of Pneumovax 23 have decreased significantly since the launch of Prevnar 13. Will Pneumovax 23 maintain its position as a recommended booster vaccine in the US?
- Prevnar 13 is recommended for adults over the age of 65 in the US. Will the UK also recommend Prevnar 13 for older adults?
- V114 is a 15-valent pneumococcal vaccine being developed by Merck & Co. If approved, will V114 replace Prevnar 13 on the market?
- Will vaccination rates change for infants? For high risk adults (19-64)? For elderly patients 65 and older?
- Will the age threshold for recommendation in the elderly be lowered, for example, from 60 to 50 years of age?
- In the US, will further age groups eventually be recommended for pneumococcal vaccination such as adolescents and adults without chronic illness?
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial) |